LOS ANGELES, June 29, 2015 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the closing of its previously announced initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share. Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. Gross proceeds to Ritter from the offering were $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses.
Aegis Capital Corp. acted as sole book-running manager for the offering.
Chardan Capital Markets, LLC and Barrington Research acted as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on June 24, 2015.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, via telephone: 212-813-1010, or via e-mail: email@example.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharma is advancing human gut health research by exploring the metabolic capacity of gut microbiota and translating the functionality of these microbiome modulators into safe and effective applications. Ritter Pharma’s lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.